McDonagh TA, Metra M, Adamo M et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14]. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368

Article  CAS  PubMed  Google Scholar 

Snipelisky D, Chaudhry SP, Stewart GC (2019) The many faces of heart failure. Card Electrophysiol Clin 11(1):11–20. https://doi.org/10.1016/j.ccep.2018.11.001. Epub 2018 Dec 24 PMID: 30717842

Article  PubMed  Google Scholar 

La Franca E, Manno G, Ajello L et al (2021) Physiopathology and diagnosis of congestive heart failure: consolidated certainties and new perspectives. Curr Probl Cardiol. 46(3):100691. https://doi.org/10.1016/j.cpcardiol.2020.100691. Epub 2020 Aug 29 PMID: 33012532

Article  PubMed  Google Scholar 

Visco V, Radano I, Campanile A et al (2022) Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Fail. 9:2909–2917

Article  PubMed  PubMed Central  Google Scholar 

Dattilo G, Laterra G, Licordari R et al (2023) The long-term benefit of sacubitril/valsartan in patients with HFrEF: a 5-year follow-up study in a real world population. J Clin Med 28(12):6247

Article  Google Scholar 

Dini FL, Carluccio E, Bitto R, Working group on heart failure of the Italian Society of Cardiology et al (2022) Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. ESC Heart Fail 9:1107–1117

PubMed  PubMed Central  Google Scholar 

Carluccio E, Dini FL, Bitto R, Working group on heart failure of the Italian Society of Cardiology et al (2022) Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study. Int J Cardiol 350:62–68

Article  PubMed  Google Scholar 

Casale M, Mezzetti M, Gigliotti De Fazio M et al (2022) Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure. ESC. Heart Fail. 9:146–154

Google Scholar 

Corrado E, Dattilo G, Coppola G et al (2022) Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur J Clin Pharmacol 78(1):19–25

Article  CAS  PubMed  Google Scholar 

Dattilo G, Bitto R, Correale M et al (2022) Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. Minerva Cardiol Angiol. 70(5):555–562

Article  PubMed  Google Scholar 

Casale M, Correale M, Laterra G et al (2021) Effects of sacubitril/valsartan in patients with high arrhythmic risk and an ICD: A Longitudinal Study. Clin Drug Investig 41(2):169–176

Article  CAS  PubMed  Google Scholar 

de Gregorio C, Laterra G, Vaccaro V et al (2020) Time-based clinical and functional achievements in real-life HF patients on ARNI treatment. Eur J Intern Med 76:115–117

Article  PubMed  Google Scholar 

Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF, Lombardi CM, Passino C, Cerbai E, Metra M, Senni M (2020) Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol 76(15):1795–1807

Article  CAS  PubMed  Google Scholar 

Infante T, Costa D, Napoli C (2021) Novel insights regarding nitric oxide and cardiovascular diseases. Angiology 72(5):411–425. https://doi.org/10.1177/0003319720979243

Article  CAS  PubMed  Google Scholar 

Aimo A, Castiglione V, Vergaro G et al (2022) The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev 27(4):1165–1171. https://doi.org/10.1007/s10741-021-10146-1

Article  CAS  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303

Article  CAS  PubMed  Google Scholar 

Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190

Article  CAS  PubMed  Google Scholar 

Trujillo ME, Ayalasomayajula S et al (2023) Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science. Clin Transl Sci. 16(12):2458–2466. https://doi.org/10.1111/cts.13677

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breitenstein S, Roessig L et al (2016) Novel sGC stimulators and sGC activators for the treatment of heart failure. Part of the Handbook of Experimental Pharmacology book series (HEP, volume 243). https://doi.org/10.1007/164_2016_100

Boettcher M, Gerisch M, Lobmeyer M et al (2020) Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet 59(11):1407–1418. https://doi.org/10.1007/s40262-020-00895-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

González-Juanatey JR, Anguita-Sánchez M, Bayes-Genís A et al (2022) Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 222(6):359–369. https://doi.org/10.1016/j.rceng.2021.12.006

Article  PubMed  Google Scholar 

Correale M, Tricarico L, Croella F, Alfieri S, Fioretti F, Brunetti ND, Inciardi RM, Nodari S (2023) Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets. Front Cardiovasc Med. 2(10):1157472

Article  Google Scholar 

Pieske B, Butler J, Filippatos G et al (2014) SOCRATES investigators and coordinators. rationale anddesign of the Soluble Guanylate Cyclase Stimulator in Heartfailure Studies (SOCRATES). Eur J Heart Fail. 16:1026–1038

Article  CAS  PubMed  Google Scholar 

Gheorghiade M, Greene SJ, Butler J et al (2015) SOCRATES-REDUCED investigators and coordinators Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314:2251–2262

Article  CAS  PubMed  Google Scholar 

Armstrong PW, Pieske B, Anstrom KJ, VICTORIA study group et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 382:1883–1893

Article  CAS  PubMed  Google Scholar 

Voors AA, Mulder H, Reyes E, VICTORIA study group et al (2021) Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur JHeart Fail 23:1313–1321. https://doi.org/10.1002/ejhf.2221

Article  CAS  Google Scholar 

McMurray JJ, Packer M, Desai AS et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062–1073. https://doi.org/10.1093/eurjhf/hft052

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aimo A, Pateras K, Stamatelopoulos K et al (2021) Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther 35:1067–1076. https://doi.org/10.1007/s10557-020-07099-2

Article  CAS  PubMed  Google Scholar 

Kang DW, Kang SH, Lee K, Nam K, Kim ES, Yoon JC, Park SK (2024) Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: systematic review and network meta-analysis. Int J Cardiol 400:131786. https://doi.org/10.1016/j.ijcard.2024.131786. Epub 2024 Jan 17 PMID: 38242507

Article  PubMed  Google Scholar 

Pagnesi M, Baldetti L, Aimo A, Inciardi RM, Tomasoni D, Vizzardi E, Vergaro G, Emdin M, Lombardi CM (2022) Prognostic benefit of new drugs for HFrEF: a systematic review and network meta-analysis. J Clin Med 11(2):348. https://doi.org/10.3390/jcm11020348

Article  CAS  PubMed  PubMed Central  Google Scholar